Lilly licenses Cipla to sell tirzepatide under a separate Indian brand

Eli Lilly and Indian drugmaker Cipla announced on October 23, 2025, that Cipla will market Lilly's tirzepatide injection under a new brand name, Yurpeak, in India ^[1]. Lilly will manufacture the drug, and Cipla will handle sales and distribution ^[1]. Tirzepatide is sold in the United States as Mounjaro and Zepbound; in India, Lilly's existing brand for the drug is Mounjaro ^[1].

Yurpeak will come as a once-weekly, pre-filled injector pen, matching the design of Lilly's Mounjaro Kwikpen ^[1]. The product will be offered in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[1]. Lilly and Cipla said Yurpeak will be priced the same as Mounjaro ^[1].

Lilly launched Mounjaro in India in late March 2025 for both diabetes and obesity treatment, initially in 2.5 mg and 5 mg vials ^[1]. India's drug regulator approved the Kwikpen device for the product in June 2025 ^[1]. Sales of the drug more than doubled within months of its India launch, according to Reuters ^[1].

Tirzepatide belongs to the GLP-1 receptor agonist class of drugs, which work by helping control blood sugar and slowing digestion, a mechanism that makes people feel full for longer ^[1]. This is the same drug class that includes semaglutide, sold in the U.S. as Ozempic, Wegovy and Rybelsus ^[1].

Why it matters for patients

This deal is specific to the Indian market and does not change how tirzepatide is sold, priced, or supplied in the United States, based on the available reporting ^[1]. U.S. patients taking Mounjaro or Zepbound will not see Yurpeak on pharmacy shelves; it is not being introduced in the U.S. ^[1].

Still, the arrangement shows how Lilly is trying to build out its presence in a large, price-sensitive market by working with a local partner rather than relying only on its own brand ^[1]. Selling the same drug under two brand names, made by Lilly but marketed separately by Cipla, is one way a manufacturer can compete for pharmacy shelf space and prescriber attention without lowering its own list price ^[1]. The source material does not specify why Lilly chose this two-brand approach or what competitive pressure prompted it, so the strategic reasoning beyond the companies' own announcement is not yet known ^[1].

For patients in the U.S. watching the broader GLP-1 market, moves like this are a sign that manufacturers are actively adjusting distribution strategies overseas as competition and demand shift. Whether this kind of arrangement could eventually affect how tirzepatide is priced or supplied in other countries, including the United States, is not addressed in the available reporting ^[1].

What happens next

The source material does not include a launch date for Yurpeak in India or details on how quickly Cipla plans to roll out the product ^[1]. It also does not specify whether Lilly plans similar multi-brand licensing arrangements in other countries ^[1]. Readers should watch for future company statements or regulatory filings for updates on Yurpeak's availability and on Lilly's broader distribution strategy ^[1].